Trials / Conditions / Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

22 registered clinical trials studyying Moderate to Severe Chronic Plaque Psoriasis — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psor NCT07362017	Vanda Pharmaceuticals	Phase 3
Completed	This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bma NCT06738277	Biocon Biologics UK Ltd	Phase 1
Active Not Recruiting	Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinic NCT06591273	Services Institute of Medical Sciences, Pakistan	Phase 1 / Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate t NCT06011733	UCB Biopharma SRL	Phase 3
Completed	A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adult NCT05975268	Shanghai Junshi Bioscience Co., Ltd.	Phase 3
Completed	To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Ch NCT05495568	Celltrion	Phase 3
Completed	A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in NCT05388916	Novartis Pharmaceuticals	—
Completed	Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psor NCT05335356	Biocon Biologics UK Ltd	Phase 3
Completed	Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Sev NCT04785326	Dong-A ST Co., Ltd.	Phase 3
Active Not Recruiting	A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis NCT03997786	Sun Pharmaceutical Industries Limited	Phase 2 / Phase 3
Completed	A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Su NCT03766685	UCB Biopharma SRL	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic P NCT03598790	UCB Biopharma SRL	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects NCT03536884	UCB Biopharma SRL	Phase 3
Completed	A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy an NCT03410992	UCB Biopharma SRL	Phase 3
Completed	Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis NCT03463187	Jiangsu HengRui Medicine Co., Ltd.	Phase 1 / Phase 2
Completed	A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adu NCT03370133	UCB Biopharma SRL	Phase 3
Completed	A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Pla NCT02223039	AbGenomics B.V Taiwan Branch	Phase 2
Completed	Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis P NCT01855880	AbGenomics B.V Taiwan Branch	Phase 2
Withdrawn	Post Marketing Observational Study on Venezuelan Patients With Psoriasis NCT01758705	AbbVie (prior sponsor, Abbott)	—
Completed	Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) NCT01076192	AbbVie (prior sponsor, Abbott)	—
Completed	A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to NCT00601107	Genzyme, a Sanofi Company	Phase 2
Completed	Community Based Trial for AMEVIVE® NCT00168753	Astellas Pharma Inc	Phase 4